John Mascarenhas, MD, discusses the mechanism of action of pacritinib and how it differs from ruxolitinib and fedratinib.
John Mascarenhas, MD, professor of medicine at Icahn School of Medicine at Mount Sinai, director of the Center of Excellence for Blood Cancers and Myeloid Disorders, and a member of The Tisch Cancer Institute, discusses the mechanism of action of pacritinib (Vonjo) and how it differs from ruxolitinib (Jakafi) and fedratinib (Inrebic).
On February 28, 2022, the FDA granted approval to pacritinib for the treatment of patients with myelofibrosis and severe thrombocytopenia, defined as a platelet count less than 50x109/L, based on positive results from 3 clinical trials.
According to Mascarenhas, pacritinib targets the JAK/STAT pathway differently than the 2 other FDA-approved JAK inhibitors.
Transcription:
0:07 | So, ruxolitinib is a JAK1/2 inhibitor and fedratinib is a selective JAK2 inhibitor. Pacritinib is a JAK2 selective inhibitor that also inhibits IRAK1, and it is likely that some of these non-JAK receptor kinase inhibition aspects of these drugs likely provide differences both in tolerability and safety but also in efficacy and have the potential to address niches.
0:41 | So, in this case, as a JAK2/IRAK1 inhibitor that down regulates the IL-1 toll like receptor mitogenome NF-κB axis, it also reduces inflammatory cytokines through a nonJAK2-dependent pathway can complement JAK2 inhibition. And it may be for this reason that one can deliver pacritinib at 2 mg twice daily to patients, particularly with thrombocytopenia, that are the hallmark of the cytopenic myelofibrosis patient, and for the spleen and symptoms which we really can't achieve with drugs like ruxolitinib.
Weighing the Triggers for Initiating JAK2 Inhibition Therapy in MF
March 23rd 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the triggers physicians need to consider when deciding to initiate therapy for patients with myelofibrosis in the first article of a 2-part series.
Read More
Lachowiez Considers the Use of Tagraxofusp in BPDCN as Bridge to SCT With Peers
March 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Curtis Lachowiez, MD, discussed targeted therapy for blastic plasmacytoid dendritic cell neoplasm and its role in patients who could receive allogeneic stem cell transplant.
Read More
Participants Discuss Treating a Patient With Myelofibrosis and Anemia
March 18th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed with participants which symptoms of myelofibrosis impact their quality of life and how they would treat a patient experiencing anemia.
Read More